Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.82 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.54 |
| ▸ | TUBB | P07437 | 4/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flubendazole SCHEMBL167185 | 1.00 | KDR (0.82) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL22321861 | 0.99 | KDR (0.80) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL8005889 | 0.95 | KDR (0.76) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL28005737 | 0.95 | KDR (0.76) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL453978 | 0.94 | KDR (0.78) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL20815724 | 0.91 | KDR (0.69) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL31704404 | 0.90 | KDR (1.00) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL6232065 | 0.90 | KDR (1.00) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Mebendazole SCHEMBL15860 | 0.89 | ABL1 (0.82) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Mebendazole SCHEMBL3429179 | 0.89 | ABL1 (0.82) | KDRMAPK1ADORA3PTGS1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| EP-4389116-B1 | PHARMACEUTICAL AQUEOUS FLUBENDAZOLE SUSPENSION | DECHRA LTD (GB) | 2025-09-10 | — | — | EP | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| EP-4140504-B1 | MICELLE MADE FROM BENZIMIDAZOLE-CARBOHYDRATE CONJUGATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTICANCER AGENT OR ANTIVIRAL AGENT COMPRISING THE SAME | BIOMETRIX TECH INC (KR) | 2025-01-15 | — | — | EP | claimed |
| EP-3907230-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT COMPRISING THE SAME | BIOMETRIX TECH INC (KR) | 2024-08-28 | — | — | EP | claimed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| EP-3972591-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | ZEPHAPHARM LTD (GB) | 2022-12-28 | — | — | EP | claimed |
| CN-114903046-A | Bactericidal composition and application thereof | 沈阳中化农药化工研发有限公司 | 2022-08-16 | — | — | CN | claimed |
| EP-3448435-B1 | PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTS | ROUSSELOT B V (NL) | 2022-06-01 | — | — | EP | claimed |
| EP-3599855-B1 | DELAYED RELEASE FEED-THROUGH VETERINARY COMPOSITIONS WITH OVICIDAL AND LARVICIDAL ACTIVITY AGAINST SUSCEPTIBLE AND RESISTANT STRAINS OF PARASITES IN RUMINANTS' FECES, USE OF THESE COMPOSITIONS, METHOD FOR DELAYING THE RELEASE OF THESE COMPOSITIONS | Champion USA LLC (US) | 2022-03-02 | — | — | EP | claimed |
| US-12582717-B2 | Protein based excipient for active pharmaceutical ingredients | DISPERSOME IP APS (NL) | 2026-03-24 | — | — | US | disclosed |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| US-12357696-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| EP-3865120-B1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-06-25 | — | — | EP | disclosed |
| EP-3974414-A1 | 5-AMINO SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PESTICIDES | Bayer AG (DE) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972591-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | Zephapharm Ltd. (GB) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022053453-A1 | AZOLE CARBOXAMIDE AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-17 | — | — | WO | disclosed |
| US-20220072136-A1 | PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTS | DISPERSOME IP APS (NL) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357696-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | SI, PIM1, PIM3 | KDR 2227/4885MAPK1 2653/4885ADORA3 3352/4885 |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | SI, PIM1, PIM3 | KDR 2227/4885MAPK1 2653/4885ADORA3 3352/4885 |
| US-12582717-B2 | Protein based excipient for active pharmaceutical ingredients | MAX, PEPD, RPS27A | KDR 4125/4885MAPK1 3721/4885ADORA3 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.